Skip to main content

Select Drug Profiles

Multiple Myeloma, Multiple Myeloma, Oncology
VISTA Final Analysis Upholds Survival Benefit of Bortezomib at 5 Years
Caroline Helwick, Caroline Helwick
Read More
Multiple Myeloma, Multiple Myeloma, Oncology
Maintenance Strategies in Elderly Patients with Myeloma Not Eligible for Transplant
Caroline Helwick, Caroline Helwick
Read More
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick, Caroline Helwick
Read More
Conference Highlights ASH
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan, Neil Canavan
Read More
Cost of Treating Myeloproliferative Neoplasms Is Significant
Neil Canavan, Neil Canavan
Read More
Conference Highlights ASH
High Morbidity Burden Borne Years Later by Survivors of Transplant
Caroline Helwick, Caroline Helwick
Read More
Leukemia, Oncology
Obinutuzumab Could Give Rituximab a Run for Its Money in Relapsed Indolent NHL
Read More
Leukemia, Oncology
Maintenance Rituximab May Be Unnecessary in FL
Caroline Helwick, Caroline Helwick
Read More
Multiple Myeloma, Multiple Myeloma, Oncology
Monoclonal Antibody Elotuzumab Promising in Multiple Myeloma
Read More
Multiple Myeloma, Multiple Myeloma, Multiple Myeloma, Oncology
Pomalidomide a Promising New Immunomodulatory Drug for Multiple Myeloma
Read More
Page 207 of 244
Results 2061 - 2070 of 2434